Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for Hard-to-Treat prostate cancer in japanese men

NCT ID NCT06104449

First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 28 times

Summary

This early-stage study tested the safety of a new drug called opevesostat (MK-5684) in 7 Japanese men with a type of advanced prostate cancer that no longer responds to standard hormone therapy and chemotherapy. The goal was to see if the drug is safe and how it works in the body. While not a cure, it aims to control the disease in patients who have few options left.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION RESISTANT PROSTATE CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • National Cancer Center Hospital East ( Site 0001)

    Kashiwa, Chiba, 277-8577, Japan

  • Toho University Sakura Medical Center ( Site 0003)

    Sakura, Chiba, 285-8741, Japan

  • Yokohama City University Medical Center ( Site 0002)

    Yokohama, Kanagawa, 232-0024, Japan

Conditions

Explore the condition pages connected to this study.